Get the Stockscreener App
2.85
0.70%
-0.02
After Hours:
2.85
Xeris Biopharma Holdings Inc stock is traded at $2.85, with a volume of 970.68K.
It is down -0.70% in the last 24 hours and up +1.42% over the past month.
Xeris Biopharma Holdings Inc is a biopharmaceutical company developing and commercializing unique therapies for patient populations in endocrinology, neurology, and gastroenterology. The company has three commercially available products, Gvoke, ready-to-use liquid glucagon for the treatment of severe hypoglycemia, Keveyis, the first FDA-approved therapy for primary periodic paralysis, and Recorlev, approved by the FDA for the treatment of endogenous hypercortisolemia in adult patients with Cushing's Syndrome. The Company also has a pipeline of development programs to bring new products forward using its proprietary formulation science, XeriSol and XeriJect.
See More
Previous Close:
$2.87
Open:
$2.88
24h Volume:
970.68K
Relative Volume:
0.65
Market Cap:
$424.65M
Revenue:
$181.41M
Net Income/Loss:
$-59.56M
P/E Ratio:
-5.4808
EPS:
-0.52
Net Cash Flow:
$-38.83M
1W Performance:
+3.26%
1M Performance:
+1.42%
6M Performance:
+28.96%
1Y Performance:
+53.23%
1-Day Range:
$2.80
$2.94
1-Week Range:
$2.705
$2.94
52-Week Range:
$1.46
$3.26
Xeris Biopharma Holdings Inc Stock (XERS) Company Profile
Name
Xeris Biopharma Holdings Inc
Sector
Industry
Phone
844-445-5704
Address
1375 WEST FULTON STREET, SUITE 1300, CHICAGO, IL
Xeris Biopharma Holdings Inc Stock (XERS) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Oct-21-22 | Initiated | Jefferies | Buy |
| Apr-28-22 | Initiated | Craig Hallum | Buy |
| Nov-17-21 | Initiated | SVB Leerink | Outperform |
| Oct-29-21 | Initiated | H.C. Wainwright | Buy |
| Apr-07-21 | Resumed | RBC Capital Mkts | Outperform |
| Feb-18-20 | Initiated | Piper Sandler | Overweight |
| Jul-16-18 | Initiated | Jefferies | Buy |
| Jul-16-18 | Initiated | Leerink Partners | Outperform |
| Jul-16-18 | Initiated | RBC Capital Mkts | Outperform |
View All
Xeris Biopharma Holdings Inc Stock (XERS) Latest News
Perhaps timely catching Xeris Biopharma Holdings Inc (XERS) would be a good idea - SETE News
Understanding the Risks of Investing in Xeris Biopharma Holdings Inc (XERS) - Knox Daily
Rhumbline Advisers Raises Stock Holdings in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Does Xeris Biopharma Holdings Inc (XERS) offer a good opportunity for investors? - SETE News
A company insider recently bought 4,515 shares of Xeris Biopharma Holdings Inc [XERS]. Should You Buy? - Knox Daily
Xeris Biopharma Holdings Inc (XERS) presents a great opportunity, but the stock is slightly overvalued - US Post News
A Guide To The Risks Of Investing In Xeris Biopharma Holdings Inc (XERS) - Knox Daily
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Bought by Bank of New York Mellon Corp - Defense World
Asset Management Group Inc. Acquires 15,000 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc (XERS) Stock: Navigating a Year of Stock Volatility - The InvestChronicle
Xeris Biopharma Holdings Inc [XERS] Records 50-Day SMA of $2.58 - Knox Daily
Analytical Lens: Exploring Xeris Biopharma Holdings Inc (XERS)’s Financial Story Through Ratios - The Dwinnex
Xeris Biopharma Holdings Inc (XERS) Becoming More Attractive for Investors - Knox Daily
Financial Analysis: Lexaria Bioscience (NASDAQ:LEXX) & Xeris Biopharma (NASDAQ:XERS) - Defense World
Healthy Upside Potential: Xeris Biopharma Holdings Inc (XERS) - SETE News
Principal Financial Group Inc. Sells 10,992 Shares of Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings Inc [XERS] stock for 10,147 USD was bought by Schmid John P. - Knox Daily
Xeris Biopharma Holdings Inc [XERS] Revenue clocked in at $181.41 million, up 21.70% YTD: What’s Next? - The DBT News
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) most popular amongst individual investors who own 53% of the shares, institutions hold 43% - Yahoo Finance
XERS: Riding the Market Waves of Growth and Decline in 2023 - The InvestChronicle
The Potential Rise in the Price of Xeris Biopharma Holdings Inc (XERS) following insiders activity - Knox Daily
Xeris Biopharma Holdings Inc (XERS) requires closer examination - US Post News
Trading Day Review: Xeris Biopharma Holdings Inc (XERS) Gains Momentum, Closing at 2.67 - The Dwinnex
Allspring Global Investments Holdings LLC Boosts Stake in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Could Be Riskier Than It Looks - Simply Wall St
Taking a look at what insiders are doing to gauge the Xeris Biopharma Holdings Inc (XERS)’s direction - Knox Daily
Xeris Biopharma Holdings Inc (XERS) Stock: A Year of Market Movement, Down and Up - The InvestChronicle
A History of Outperforming Analyst Forecasts and Beating the Odds: Xeris Biopharma Holdings Inc (XERS) - SETE News
Examining Xeris Biopharma Holdings Inc (XERS) stock is warranted - US Post News
Xeris Biopharma Holdings Inc [XERS] Records 200-Day SMA of $2.27 - Knox Daily
Xeris Biopharma Holdings Inc (XERS) shows promising results - US Post News
Trading Day Triumph: Xeris Biopharma Holdings Inc (XERS) Ends at 2.88, a 2.86 Surge/Plunge - The Dwinnex
The time has not yet come to remove your chips from the table: Xeris Biopharma Holdings Inc (XERS) - SETE News
This Data Shows Just How Strong Xeris Biopharma Holdings Inc (NASDAQ: XERS) Stock Is - Stocks Register
Xeris Biopharma Holdings Inc’s Shares Reel: 48.97% Quarterly Revenue Decline Amid 432.84M Market Cap - The InvestChronicle
Xeris Biopharma Holdings Inc [XERS] Records 50-Day SMA of $2.35 - Knox Daily
Xeris Biopharma Holdings Inc (XERS) Stock: A Year of Stock Market Dynamics - The InvestChronicle
Xeris to Participate in Upcoming Investor Conferences - StockTitan
Xeris to Participate in Upcoming Investor Conferences - Business Wire
Gaining Ground: Xeris Biopharma Holdings Inc (XERS) Closes Lower at 2.70, Down -0.74 - The Dwinnex
How should investors view Xeris Biopharma Holdings Inc (XERS)? - US Post News
Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) Shares Sold by California State Teachers Retirement System - Defense World
Xeris Biopharma And 2 Other Penny Stocks Insiders Are Buying - MSN
Investing in Xeris Biopharma Holdings Inc (XERS): What You Must Know - Knoxdaily.com
XERS (Xeris Biopharma Holdings) EPS (Basic) : $-0.42 (TTM As of Jun. 2024) - GuruFocus.com
A new trading data show Xeris Biopharma Holdings Inc (XERS) is showing positive returns. - SETE News
Xeris Biopharma Holdings (FRA:2B30) Cash-to-Debt : 0.29 (As of Jun. 2024) - GuruFocus.com
Xeris Biopharma Holdings (FRA:2B30) Long-Term Debt & Capita - GuruFocus.com
Xeris Biopharma (NASDAQ:XERS) Rating Reiterated by HC Wainwright - Defense World
Price T Rowe Associates Inc. MD Boosts Stock Position in Xeris Biopharma Holdings, Inc. (NASDAQ:XERS) - Defense World
Xeris Biopharma Holdings (FRA:2B30) Momentum Rank : 1 (As of Aug. 16, 2024) - GuruFocus.com
Xeris Biopharma Holdings Inc Stock (XERS) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.05%
4.86%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):